Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liproca Depot in Localized Prostate Cancer
NCT00913263Phase 2Completed
- Sponsor
- LIDDS AB
- Start
- Jun 2009
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 2-hydroxyflutamide depot in prostate cancer (PCa), sponsored by LIDDS AB. Primary endpoint: Proportion of Patients Showing PSA Nadir at 6 months. Started Jun 2009; status: completed.
02
Drugs
2-hydroxyflutamide depot
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00913263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00913263.